Market Cap | 95.08M | P/E | - | EPS this Y | -57.10% | Ern Qtrly Grth | - |
Income | -53.73M | Forward P/E | -1.95 | EPS next Y | -17.60% | 50D Avg Chg | -14.00% |
Sales | 9.28M | PEG | -0.12 | EPS past 5Y | - | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 0.78 | EPS next 5Y | 10.90% | 52W High Chg | -64.00% |
Recommedations | 1.30 | Quick Ratio | 11.87 | Shares Outstanding | 43.70M | 52W Low Chg | 92.00% |
Insider Own | 6.23% | ROA | -21.51% | Shares Float | 24.76M | Beta | 0.46 |
Inst Own | 74.24% | ROE | -48.27% | Shares Shorted/Prior | 1.12M/1.06M | Price | 2.67 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 42,648 | Target Price | 12.00 |
Oper. Margin | -1,658.79% | Earnings Date | - | Volume | 34,748 | Change | -2.55% |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
HC Wainwright & Co. | Buy | Jul 2, 24 |
JMP Securities | Market Outperform | Jun 26, 24 |
HC Wainwright & Co. | Buy | Jun 26, 24 |
JMP Securities | Market Outperform | Jun 4, 24 |
HC Wainwright & Co. | Buy | Jun 3, 24 |
HC Wainwright & Co. | Buy | May 24, 24 |
JMP Securities | Market Outperform | May 6, 24 |
HC Wainwright & Co. | Buy | May 6, 24 |
JMP Securities | Market Outperform | Apr 3, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | Director Director | Jan 06 | Buy | 2.21 | 1,853,000 | 4,095,130 | 5,701,056 | 01/10/23 |
Seidel-Dugan Cynthia | Chief Scientific Off.. Chief Scientific Officer | Jan 06 | Option | 3.17 | 39,731 | 125,947 | 164,888 | 01/14/22 |